button bars forest bayes pooled summary circles
 
deaths (OS)

non squamous - mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) non squamous cell - mNSCLC - L1 non squamous - mNSCLC - L1 - all population

versus atezolizumab plus carboplatin plus nab-paclitaxel
atezolizumab plus carboplatin plus nab-paclitaxel vs. atezolizumab plus carboplatin plus nab-paclitaxel 1 certainty unassessablestatistically conclusive-18%
versus bevacizumab plus carboplatin and paclitaxel
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel vs. bevacizumab plus carboplatin and paclitaxel 1 certainty unassessable-22%
atezolizumab plus carboplatin plus paclitaxel vs. bevacizumab plus carboplatin and paclitaxel 1 certainty unassessable-14%

non squamous - mNSCLC - L1 - Wild Type (WT) metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) non squamous cell - mNSCLC - L1 non squamous - mNSCLC - L1 - Wild Type (WT)

versus bevacizumab plus carboplatin and paclitaxel
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel vs. bevacizumab plus carboplatin and paclitaxel 2 certainty unassessablestatistically conclusive-20%
versus carboplatin plus nab-paclitaxel
atezolizumab plus carboplatin plus nab-paclitaxel vs. carboplatin plus nab-paclitaxel 1 certainty unassessablestatistically conclusive-19%
versus pemetrexed plus platin
atezolizumab plus pemetrexed and platin vs. pemetrexed plus platin 1 certainty unassessable-17%
pembrolizumab and pemetrexed plus platin vs. pemetrexed plus platin 1 certainty unassessable-9%
versus placebo plus SoC
pembrolizumab plus SoC vs. placebo plus SoC 1 certainty unassessablestatistically conclusive-47%

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons